碧生源(00926.HK)料本年度虧損約6,500萬至8,500萬人幣
碧生源(00926.HK)表示,根據集團管理賬目及對銷售業績的初步預測,截至2022年12月31日止年度收入預期將按年減少約12%至16%,年內將可能錄得淨虧損約6,500萬至8,500萬元人民幣,當中未包括長期資產減值測試及所投資非上市公司股權公允價值變動有可能帶來的減值虧損。
公司解釋,本年度預期錄得淨虧損,主要由於期內受市場變化及價格競爭的影響,主營產品減肥藥品預計出貨量按年下降約40%;下半年的市場營銷及促銷開支、廣告費用及研究及開發成本較上半年有所增加;以及疫情對集團產品生產、物流配送及業務銷售帶來不同程度的影響。(gc/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.